OBJECTIVE: To investigate the longitudinal changes of gut structural damage in chronically untreated HIV infection. DESIGN: This is a 96-week prospective, single-site, cohort study of antiretroviral therapy-naive HIV-infected participants. METHODS: Intestinal fatty acid-binding proteins (I-FABP) were used as a surrogate marker of gut structural damage. We assessed changes in I-FABP over 96 weeks and examined the associations between I-FABP, HIV variables, and inflammation. Spearman's correlations and linear mixed-effect models were used to study relationships among variables. RESULTS: A total of 63 HIV-infected, antiretroviral therapy-naive patients were included in this analysis. At baseline, 76% were male; 62% were African American, with median age and body mass index of 40 years and 27 kg/m, respectively. Median HIV-RNA and CD4 T-cell counts were 5520 copies per milliliter and 588 cells per mm, respectively. I-FABP significantly increased from baseline to week 96 (mean change +333.9 pg/mL; P = 0.03), and this increase was associated with viral replication (rho = +0.4; P = 0.03). I-FABP levels were found to be associated with markers of inflammation: sTNFR-II (rho = 0.4, P = 0.02) and sVCAM-1 (rho = 0.04; P < 0.01) at all study time points. Lower baseline CD4 T-cell counts was found to be independently associated with I-FABP progression after adjusting for baseline characteristic variables (P = 0.02). CONCLUSION: Gut structural damage is an ongoing process in the chronic phase of untreated HIV infection and is largely dependent on viral replication. I-FABP was found to be associated with worse immune function, increased inflammation, and viremia in chronically untreated HIV infection, supporting its role as a biomarker of intestinal barrier dysfunction.
OBJECTIVE: To investigate the longitudinal changes of gut structural damage in chronically untreated HIV infection. DESIGN: This is a 96-week prospective, single-site, cohort study of antiretroviral therapy-naive HIV-infectedparticipants. METHODS: Intestinal fatty acid-binding proteins (I-FABP) were used as a surrogate marker of gut structural damage. We assessed changes in I-FABP over 96 weeks and examined the associations between I-FABP, HIV variables, and inflammation. Spearman's correlations and linear mixed-effect models were used to study relationships among variables. RESULTS: A total of 63 HIV-infected, antiretroviral therapy-naive patients were included in this analysis. At baseline, 76% were male; 62% were African American, with median age and body mass index of 40 years and 27 kg/m, respectively. Median HIV-RNA and CD4 T-cell counts were 5520 copies per milliliter and 588 cells per mm, respectively. I-FABP significantly increased from baseline to week 96 (mean change +333.9 pg/mL; P = 0.03), and this increase was associated with viral replication (rho = +0.4; P = 0.03). I-FABP levels were found to be associated with markers of inflammation: sTNFR-II (rho = 0.4, P = 0.02) and sVCAM-1 (rho = 0.04; P < 0.01) at all study time points. Lower baseline CD4 T-cell counts was found to be independently associated with I-FABP progression after adjusting for baseline characteristic variables (P = 0.02). CONCLUSION: Gut structural damage is an ongoing process in the chronic phase of untreated HIV infection and is largely dependent on viral replication. I-FABP was found to be associated with worse immune function, increased inflammation, and viremia in chronically untreated HIV infection, supporting its role as a biomarker of intestinal barrier dysfunction.
Authors: Peter W Hunt; Elizabeth Sinclair; Benigno Rodriguez; Carey Shive; Brian Clagett; Nicholas Funderburg; Janet Robinson; Yong Huang; Lorrie Epling; Jeffrey N Martin; Steven G Deeks; Curtis L Meinert; Mark L Van Natta; Douglas A Jabs; Michael M Lederman Journal: J Infect Dis Date: 2014-04-21 Impact factor: 5.226
Authors: Irini Sereti; Shelly J Krebs; Nittaya Phanuphak; James L Fletcher; Bonnie Slike; Suteeraporn Pinyakorn; Robert J O'Connell; Adam Rupert; Nicolas Chomont; Victor Valcour; Jerome H Kim; Merlin L Robb; Nelson L Michael; Daniel C Douek; Jintanat Ananworanich; Netanya S Utay Journal: Clin Infect Dis Date: 2016-10-12 Impact factor: 9.079
Authors: Ma Somsouk; Jacob D Estes; Claire Deleage; Richard M Dunham; Rebecca Albright; John M Inadomi; Jeffrey N Martin; Steven G Deeks; Joseph M McCune; Peter W Hunt Journal: AIDS Date: 2015-01-02 Impact factor: 4.177
Authors: Netanya G Sandler; Handan Wand; Annelys Roque; Matthew Law; Martha C Nason; Daniel E Nixon; Court Pedersen; Kiat Ruxrungtham; Sharon R Lewin; Sean Emery; James D Neaton; Jason M Brenchley; Steven G Deeks; Irini Sereti; Daniel C Douek Journal: J Infect Dis Date: 2011-01-20 Impact factor: 5.226
Authors: Molly R Perkins; Istvan Bartha; J Katherina Timmer; Julia C Liebner; David Wolinsky; David Wollinsky; Huldrych F Günthard; Christoph Hauser; Enos Bernasconi; Matthias Hoffmann; Alexandra Calmy; Manuel Battegay; Amalio Telenti; Daniel C Douek; Jacques Fellay Journal: J Infect Dis Date: 2015-02-20 Impact factor: 5.226
Authors: Vanessa El Kamari; Corrilynn O Hileman; Pierre M Gholam; Manjusha Kulkarni; Nicholas Funderburg; Grace A McComsey Journal: Clin Gastroenterol Hepatol Date: 2018-06-14 Impact factor: 11.382
Authors: Adam J Ericsen; Michael Lauck; Mariel S Mohns; Sarah R DiNapoli; James P Mutschler; Justin M Greene; Jason T Weinfurter; Gabrielle Lehrer-Brey; Trent M Prall; Samantha M Gieger; Connor R Buechler; Kristin A Crosno; Eric J Peterson; Matthew R Reynolds; Roger W Wiseman; Benjamin J Burwitz; Jacob D Estes; Jonah B Sacha; Thomas C Friedrich; Jason M Brenchley; David H O'Connor Journal: PLoS Pathog Date: 2016-12-07 Impact factor: 6.823
Authors: Tecla M Temu; Stephen J Polyak; Jerry S Zifodya; Celestine N Wanjalla; John R Koethe; Sarah Masyuko; Jerusha Nyabiage; John Kinuthia; Ana L Gervassi; Julius Oyugi; Stephanie Page; Carey Farquhar Journal: Open Forum Infect Dis Date: 2020-09-12 Impact factor: 3.835